https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2017 » March
Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]

New oral blood thinner rivaroxaban from Bayer and Jannsen shown to cut recurrence of life-threatening blood clots

Bayer and Janssen Pharmaceuticals have revealed that their jointly developed oral blood thinner Xarelto (rivaroxaban) had considerably brought down the risk of recurring formation of life-threatening blood clots in the vein as per the findings of their late-breaking study. Rivaroxaban Blood Thinner Clinical Trial This, they demonstrated in a blood thinner clinical trial dubbed EINSTEIN CHOICE. […]

Continue reading …
Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]

Continue reading …
Amgen cholesterol injection Repatha reduces heart attack, stroke chances

Amgen cholesterol injection Repatha (evolocumab) has been demonstrated to have cut heart attack and stroke risk by 20% in a phase 3 cardiovascular outcomes study featuring 27,564 patients with heart diseases. Amgen Cholesterol Trial for Repatha Cholesterol Injection During the trial, it was proven that by maximum reduction of low-density lipoprotein cholesterol (LDL-C) levels (bad cholesterol) […]

Continue reading …
Tigenix’ heart attack stem cell therapy trial delivers positive results

TiGenix has announced that its cardiac stem cell study assessing its heart attack stem cell therapy with AlloCSC-01 was successful in patients having the risk of heart failure following a coronary attack. Tigenix Heart Attack Stem Cell Therapy with AlloCSC-01 The Belgium biopharma stated that its Phase I/II study of donor-derived expanded cardiac stem cells (AlloCSC) […]

Continue reading …
Servier, Pfizer given FDA green signal for lymphoblastic leukemia drug

The US Food and Drug Administration (FDA) has given the green signal to Servier and Pfizer to carry out the clinical development of their UCART19 lymphoblastic leukemia drug for relapsed/refractory acute lymphoblastic leukemia treatment. In this regard, the FDA granted the pharmas with the Investigational New Drug (IND) clearance for the allogeneic, gene-edited cellular therapy […]

Continue reading …
Actelion’s Ledaga Chlormethine Gel for CTCL MF treatment gets EC approval

Actelion recent news : The European Commission (EC) has approved Actelion Pharmaceuticals’ marketing authorization for its Ledaga Chlormethine Gel 160 micrograms/g for cutaneous T-cell lymphoma mycosis fungoides-type treatment, shortened as CTCL MF treatment. Ledaga Chlormethine Gel Details Approval of the topical, daily once and colorless gel by the EC comes in the wake of the […]

Continue reading …
AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]

Continue reading …
Noctiva becomes first FDA approved treatment for nocturia syndrome

Serenity Pharmaceuticals’ nasal spray to treat the nocturnal polyuria syndrome in adults, Noctiva (desmopressin acetate) has secured the US FDA approval. Nocturnal polyuria syndrome or simply nocturia syndrome is a condition where a person has to wake up more than twice during the night to urinate. Noctiva is now the first treatment for nocturnal urine […]

Continue reading …
Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]

Continue reading …
Page 1 of 212